Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Status:
Completed
Trial end date:
2017-12-11
Target enrollment:
Participant gender:
Summary
Preclinical data in lung cancer cell lines showed that EGFR mutation can potentially be a
positive predictor for sensitivity to BKM120. Furthermore, when the erlotinib-resistant model
H1975 (LR858 and T790M mutation) was treated with BKM120, significant tumor control was
observed (Novartis internal data). Therefore, combining BKM120 with erlotinib could
potentially down-modulate PI3K-Akt activity resulting in a synergistic effect on cell growth
inhibition and enhancing the response to erlotinib.